Advanced treatment options include several biologics that target specific signaling pathways that trigger EoE (e.g., human anti–IL-4 receptor α antibody dupilumab, anti–IL-13 antibodies [e.g., cendakimab]) and eosinophilic infiltration of the tissue (e.g., Siglec-8 inhibitor lirentelimab, anti–IL-5RA antibody benralizumab, and anti–IL-5 antibodies mepolizumab and reslizumab). Here, IL13 is linked to eosinophilic esophagitis.